Sugi Predict

Sugi Predict / Compounds / SCHEMBL21765758

SCHEMBL21765758

SCHEMBL21765758

COC(=O)C(C(=O)OC)C(=O)C1(n2cccc2-c2ccc(F)cc2)CCCC1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 2/20 0.35
▸ SLC6A3 Q01959 2/20 0.35
▸ TSHR P16473 2/20 0.34
▸ KDM4E B2RXH2 2/20 0.33
▸ EGLN1 Q9GZT9 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ GSK3A P49840 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ FAAH O00519 1/20 0.33
▸ NOS3 P29474 2/20 0.32
▸ NOS1 P29475 2/20 0.32
▸ NOS2 P35228 2/20 0.32
▸ PTGS2 P35354 2/20 0.32
▸ ITGB1 P05556 1/20 0.32
▸ ITGA4 P13612 1/20 0.32
▸ ITGB7 P26010 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21765755 0.99 SLC6A4 (0.34) SLC6A4SLC6A3TSHRKDM4EEGLN1
SCHEMBL21765764 0.90 EGLN1 (0.33) EGLN1ITGB1ITGA4
SCHEMBL21765817 0.90 KMT2A (0.37) KDM4EEGLN1
SCHEMBL21765532 0.89 FAAH (0.36) SLC6A3KDM4EGSK3BFAAH
SCHEMBL21765631 0.89 ACHE (0.36) SLC6A4SLC6A3KDM4EEGLN1NOS2
SCHEMBL21765637 0.88 KMT2A (0.37) TSHRKDM4EEGLN1FAAH
SCHEMBL21765773 0.88 ACHE (0.36) SLC6A4SLC6A3KDM4EEGLN1NOS2
SCHEMBL21765647 0.88 FAAH (0.38) TSHRKDM4EGSK3BHSD17B10FAAH
SCHEMBL21765826 0.87 KMT2A (0.37) KDM4EEGLN1CYP2C9CYP2C19
SCHEMBL21747358 0.86 FABP4 (0.35) KDM4EEGLN1FAAHPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11970495-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-30 — — US disclosed
US-11945817-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2024-04-02 — — US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 — — US disclosed
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-17 — — US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 — — US disclosed
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2023-08-03 — — US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 — — US disclosed
US-11655249-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2023-05-23 — — US disclosed
EP-3613742-B1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE KIND PHARMACEUTICAL (CN) 2022-12-07 — — EP disclosed
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2021-08-19 — — US disclosed
CN-113004271-A Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-06-22 — — CN disclosed
US-11021478-B2 Indolizine derivatives and their application in medicine KIND PHARMACEUTICAL (CN) 2021-06-01 — — US disclosed
CN-108484598-B Indolizine derivative and application thereof in medicine 杭州安道药业有限公司 2021-03-02 — — CN disclosed
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE KIND PHARMACEUTICAL (CN) 2020-05-28 — — US disclosed
EP-3613742-A1 INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE Kind Pharmaceutical (CN) 2020-02-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257379-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 SLC6A4 28/4885SLC6A3 132/4885TSHR 2950/4885
US-11021478-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 SLC6A4 28/4885SLC6A3 132/4885TSHR 2950/4885
US-11970495-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 SLC6A4 28/4885SLC6A3 132/4885TSHR 2950/4885
US-20230242527-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 SLC6A4 28/4885SLC6A3 132/4885TSHR 2950/4885
US-11945817-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 SLC6A4 28/4885SLC6A3 132/4885TSHR 2950/4885
US-20210253570-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 SLC6A4 28/4885SLC6A3 132/4885TSHR 2950/4885
US-11655249-B2 Indolizine derivatives and their application in medicine INMT, IDO1, IDO2 SLC6A4 28/4885SLC6A3 132/4885TSHR 2950/4885
US-20200165242-A1 INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE INMT, IDO1, IDO2 SLC6A4 28/4885SLC6A3 132/4885TSHR 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.